Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First filing for Imutec's Virulizin

Nov. 21, 1996

Final phase II data presented for Biomira's therapeutic cancer vaccine

Nov. 15, 1996

Ovarian cancer vaccine enters pivotal trials in Europe

Nov. 8, 1996

Apoptosis-inducing MAb from Chugai

Nov. 8, 1996

MAb 1DT3-D disclosed for treatment of B-cell lymphoma

Oct. 25, 1996

HER2/neu peptide fragment provokes immune response against tumor cells

Oct. 18, 1996

Ovarian cancer vaccine enters phase II/III trials

Oct. 11, 1996

Patent coverage for The Immune Response Corporation's colon cancer vaccine

Oct. 11, 1996

Chemokine polypeptide from Human Genome Sciences has multiple potential uses

Oct. 11, 1996

Combination therapy Maxamine/IL-2 effective in extending remission time & preventing relapse

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.